Navigation Links
Deflazacort in Duchenne Muscular Dystrophy
Date:3/24/2016

LONDON, March 24, 2016 /PRNewswire/ --

US Neurology, the peer-reviewed journal, has published an article summarizing the benefits and risks of deflazacort in Duchenne muscular dystrophy.

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO)

Duchenne muscular dystrophy (DMD) is a devastating disorder that is the most common and severe form of childhood onset muscular dystrophy. While guidelines exist that promote a multidisciplinary approach to treatment of DMD, surveys have identified inconsistent adherence to the recommendations. This is particularly highlighted by the variability in the prescriptive habits of corticosteroids, which have a long history of literature supporting their use in DMD. Relatively recent publications have uncovered differences between countries in the prescription patterns of steroid regimens. Currently, treatment recommendations lack comparative data on the efficacy and safety of alternative dosing regimens of corticosteroids. New research is being conducted to help understand the benefits and risks of the most commonly used glucocorticoid regimens in DMD. Deflazacort is a glucocorticoid corticosteroid that is currently seeking approval in the U.S. This article summarizes the relevant published literature on deflazacort to help inform DMD-treating physicians on its impact on the disease.

The full peer-reviewed, open-access article is available here:

href="http://doi.org/10.17925/USN.2016.12.01.17" rel="nofollow">http://doi.org/10.17925/USN.2016.12.01.12

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishes US Neurology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:
Carla Denaro - Managing Editor
+44 (0) 207 193 6093
managingeditor@touchmedicalmedia.com

Providing practical opinion to support best practice for busy healthcare professionals.



'/>"/>
SOURCE Touch Medical Media
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
2. New Evidence Published in Muscle and Nerve on Measuring 6-Minute Walk Distance in Duchenne Muscular Dystrophy
3. PPMD to Lead Duchenne Community in Developing Draft Guidance to Accelerate Drug Development and FDA Review
4. PTC Therapeutics Completes Enrollment of Landmark Trial in Duchenne Muscular Dystrophy
5. Expected Launch of First Disease-Modifying Therapies Through 2023 Will Revolutionize Treatment of Duchenne Muscular Dystrophy
6. ARMGO Pharma and Servier Announce Advancement of Rycal ARM210/S48168 into Clinical Stage Program Targeting Duchenne Muscular Dystrophy
7. Parent Project Muscular Dystrophy and Foundation to Eradicate Duchenne Award $1 Million Grant to ReveraGen BioPharma
8. EspeRares Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy
9. Global Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Market 2015 - Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
10. Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
11. Global Duchenne Muscular Dystrophy Drugs Market 2015-2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 The global market ... with the top three companies, namely Shimadzu Corporation, Thermo ... significant 49% of the overall market in 2015, observes ... landscape is intensely competitive and has few players, most ... These factors have restricted the entry of new players ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ... cancer and other unmet medical needs, announced today ... Cancer Research annual meeting.  The first poster to ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 in ... to be presented on April 4 is entitled ...
Breaking Medicine Technology:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... treatment, with or without a referral. Sleep apnea is often left untreated because patients ... morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of ...
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
Breaking Medicine News(10 mins):